SlideShare a Scribd company logo
Learning objectives
 At the end of the module, the participants will be
able to:
– Identify adverse events following immunization (AEFIs)
– Explain how to report AEFIs
What is an AEFI?
1
Which AEFIs are reported?
3
Key issues
How likely are AEFIs after
vaccinations
2
Adverse Event Following Immunization
(AEFI)
 What is an AEFI?
– Any untoward medical occurrence
– Takes place after an immunization
– Causes concern
– it may not necessarily have a causal relationship with the
usage of the vaccine
 How are AEFIs categorized?
Type Severity
- Vaccine reaction
- Programme error
- Coincidental
- Injection reaction
- Unknown
- Minor
- Severe
• Serious
• Non-serious
Programme errors
 Errors in vaccine preparation, handling, storage, or
administration
 Preventable
 Often constitute the greatest proportion of AEFIs
 Identification and correction are of great importance
 Examples:
– Non-sterile injection
– Injection at incorrect site
– Administration of frozen vaccine
Coincidental events
 Occur after vaccination, but not caused by the vaccine or its
administration
 Occur during infancy when illnesses are common and
congenital or early neurological conditions become apparent
 Onset temporally associated with vaccination, and inevitable
when vaccinating these age groups
 Applying normal incidence of disease and death in these age
groups along with coverage allows estimation of expected
numbers of coincidental events after immunization
Injection reactions
 Immunization anxiety-related reactions in anticipation
to and as a result of an injection of any kind
 Not related to the vaccine but to fear of the injection
 You may encounter 4 types of injection reactions :
– Fainting
– Hyperventilation
– Vomiting
– Convulsions
Vaccine reactions can be classified into two
levels of severity
 Minor reactions
– Usually occur within few
hours
– Resolve quickly
– Pose little danger
– Local: pain, swelling, redness
at injection site
– Systemic: fever, malaise,
muscle pain, headache, or loss
of appetite
 Severe reactions- require
timely and appropriate
management
– Usually do not result in long-
term problems
– Can be disabling
– Are rarely life threatening
– Include seizures and allergic
reactions caused by body’s
reaction to a particular
component in a vaccine
Some severe events can be SERIOUS
A serious AEFI- Any untoward medical
occurrence that at any dose:
– Results in death
– Is life threatening
– Requires in-patient hospitalization or prolongation
of existing hospitalization
– Results in persistent or significant disability or
incapacity
The difference between serious and severe
adverse events
 A severe reaction is a broader term which includes SERIOUS
reactions + reactions that do not necessarily lead to long term problems.
 Severe reactions must be reported
Objectives of AEFI surveillance
Rapidly detect and respond to AEFI
Identify, correct and prevent immunization error related reactions
Facilitate AEFI causality assessment
Recognize AEFI clustering including mild and/or “expected” AEFI
Identify potential safety signals and generate hypotheses
Generate information for vaccine safety communication
Which AEFIs should be reported?
 Any severe events or AEFI that is of concern to the parents
or health care worker
Serious
AEFI
Potential
immunization
error
Cluster
Parental
concern
Communit
y concern
Unexpected
relationship
with
vaccination
Unexpecte
d
frequency
AEFI Case selection for Reporting*
Reporter
should NOT
assess
causality
* Events to be reported according to context - Routine
surveillance, new vaccine, mass campaign etc
 Report the event through existing AEFI reporting systems
established by national immunization programs
National
authorities
Community, district, and
regional levels
Signs or symptoms
believed to be related
to the vaccine
Where to report AEFI's
Conducting an AEFI investigation
 Some AEFI reports will need further investigation by
the immunization programme managers
 Components of AEFI investigation:
– Identify specifications of implicated vaccine
– Examine operational aspects of the programme which may have
led to immunization errors
– Search for other potential AEFI cases/clustering
– Compare background risk to reported rate of AEFI
– Confirm (or propose) the diagnosis and determine outcome
– In collaboration with experts, determine if AEFI was vaccine-
related
What information should an AEFI report
contain?
 Client information
 Details about the vaccine
– Type
– Date
– Manufacturer
– Lot/expiration date
– Site/route of immunization, etc.
 Description of adverse event(s)
and any associated events
 Medical and treatment history
 Reporter details
Communication with caretakers in case of
an AEFI
 Reassure the caretaker
 Admit uncertainty
 Convey that the AEFI will be reported and
investigated fully
 Keep the community informed with follow-up
information
Key messages
 AEFIs can be minor or severe (which include serious events)
 AEFIs should be reported through existing AEFI reporting
systems/forms
 The safety profile of IPV is excellent
 Most infants who get IPV do not experience any side effects
 In case of an AEFI
– Reassure the caretaker
– Admit uncertainty
– Investigate fully
– Keep the community informed
End of module
Thank you
for your attention!

More Related Content

What's hot

Vigilance
VigilanceVigilance
Vigilance
Alisha Bansal
 
Adr reporting ppt
Adr reporting pptAdr reporting ppt
Adr reporting ppt
RimaSingh14
 
Aefippt
AefipptAefippt
Aefippt
DrGulzar1
 
Drug induced dermal disorders ppt by Salva Safdar
Drug induced dermal disorders ppt by Salva SafdarDrug induced dermal disorders ppt by Salva Safdar
Drug induced dermal disorders ppt by Salva Safdar
PARUL UNIVERSITY
 
Introduction to Adverse Drug Reactions
Introduction to Adverse Drug ReactionsIntroduction to Adverse Drug Reactions
Introduction to Adverse Drug Reactions
Abhik Seal
 
Periodic Safety Update Report (PSUR)
Periodic Safety Update Report (PSUR)Periodic Safety Update Report (PSUR)
Periodic Safety Update Report (PSUR)
Dr. Rohith K Nair
 
CLINICAL PHARMACY MANUAL
CLINICAL PHARMACY MANUALCLINICAL PHARMACY MANUAL
CLINICAL PHARMACY MANUAL
anamsohail29
 
Drug and therapeutic committee
Drug and therapeutic committee Drug and therapeutic committee
Drug and therapeutic committee
Jisa Anna M
 
Prescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage SystemsPrescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage Systems
Satish Veerla
 
Post marketing surveillance
Post marketing surveillancePost marketing surveillance
Post marketing surveillance
Dr. Vijesha Soni
 
medDRA SMQ TOPIC.pptx
medDRA SMQ TOPIC.pptxmedDRA SMQ TOPIC.pptx
medDRA SMQ TOPIC.pptx
VermaG3
 
Pharmacovigilance (pv)
Pharmacovigilance (pv)Pharmacovigilance (pv)
Pharmacovigilance (pv)
Reena Titoria
 
IDSP- Integrated Disease Surveillance Programme
IDSP- Integrated Disease Surveillance ProgrammeIDSP- Integrated Disease Surveillance Programme
IDSP- Integrated Disease Surveillance Programme
Gaurav Kamboj
 
Patient counseling on epilepsy.pptx
Patient counseling on epilepsy.pptxPatient counseling on epilepsy.pptx
Patient counseling on epilepsy.pptx
Archana Chavhan
 
Syphilis in pregnancy-final_version
Syphilis in pregnancy-final_versionSyphilis in pregnancy-final_version
Syphilis in pregnancy-final_version
NAIF AL SAGLAN
 
Causality Assessment ADR.pdf
Causality Assessment ADR.pdfCausality Assessment ADR.pdf
Causality Assessment ADR.pdf
Dr. Ramesh Bhandari
 
Defined daily dose-DDD
Defined daily dose-DDDDefined daily dose-DDD
Defined daily dose-DDD
MubasheeraMg
 
Who causality assessment scale
Who causality assessment scaleWho causality assessment scale
Who causality assessment scale
SHARIQUE RAZA
 
AEFI guidelines
AEFI guidelinesAEFI guidelines
AEFI guidelines
Prabir Chatterjee
 
ADR reporting form_version 1.3
ADR reporting form_version 1.3ADR reporting form_version 1.3
ADR reporting form_version 1.3
Manjeet Singh, Pharm D
 

What's hot (20)

Vigilance
VigilanceVigilance
Vigilance
 
Adr reporting ppt
Adr reporting pptAdr reporting ppt
Adr reporting ppt
 
Aefippt
AefipptAefippt
Aefippt
 
Drug induced dermal disorders ppt by Salva Safdar
Drug induced dermal disorders ppt by Salva SafdarDrug induced dermal disorders ppt by Salva Safdar
Drug induced dermal disorders ppt by Salva Safdar
 
Introduction to Adverse Drug Reactions
Introduction to Adverse Drug ReactionsIntroduction to Adverse Drug Reactions
Introduction to Adverse Drug Reactions
 
Periodic Safety Update Report (PSUR)
Periodic Safety Update Report (PSUR)Periodic Safety Update Report (PSUR)
Periodic Safety Update Report (PSUR)
 
CLINICAL PHARMACY MANUAL
CLINICAL PHARMACY MANUALCLINICAL PHARMACY MANUAL
CLINICAL PHARMACY MANUAL
 
Drug and therapeutic committee
Drug and therapeutic committee Drug and therapeutic committee
Drug and therapeutic committee
 
Prescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage SystemsPrescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage Systems
 
Post marketing surveillance
Post marketing surveillancePost marketing surveillance
Post marketing surveillance
 
medDRA SMQ TOPIC.pptx
medDRA SMQ TOPIC.pptxmedDRA SMQ TOPIC.pptx
medDRA SMQ TOPIC.pptx
 
Pharmacovigilance (pv)
Pharmacovigilance (pv)Pharmacovigilance (pv)
Pharmacovigilance (pv)
 
IDSP- Integrated Disease Surveillance Programme
IDSP- Integrated Disease Surveillance ProgrammeIDSP- Integrated Disease Surveillance Programme
IDSP- Integrated Disease Surveillance Programme
 
Patient counseling on epilepsy.pptx
Patient counseling on epilepsy.pptxPatient counseling on epilepsy.pptx
Patient counseling on epilepsy.pptx
 
Syphilis in pregnancy-final_version
Syphilis in pregnancy-final_versionSyphilis in pregnancy-final_version
Syphilis in pregnancy-final_version
 
Causality Assessment ADR.pdf
Causality Assessment ADR.pdfCausality Assessment ADR.pdf
Causality Assessment ADR.pdf
 
Defined daily dose-DDD
Defined daily dose-DDDDefined daily dose-DDD
Defined daily dose-DDD
 
Who causality assessment scale
Who causality assessment scaleWho causality assessment scale
Who causality assessment scale
 
AEFI guidelines
AEFI guidelinesAEFI guidelines
AEFI guidelines
 
ADR reporting form_version 1.3
ADR reporting form_version 1.3ADR reporting form_version 1.3
ADR reporting form_version 1.3
 

Similar to AEFI.pdf

AEFI.ppt
AEFI.pptAEFI.ppt
AEFI.ppt
Mittal Rathod
 
immunization dnm4 lesson 4.pptx
immunization              dnm4 lesson 4.pptximmunization              dnm4 lesson 4.pptx
immunization dnm4 lesson 4.pptx
AnthonyMatu1
 
AEFI monitoring for COVID-19 vaccination
AEFI monitoring for COVID-19 vaccinationAEFI monitoring for COVID-19 vaccination
AEFI monitoring for COVID-19 vaccination
Subha Deep
 
India AEFI guidelines final draft document
India AEFI guidelines final draft documentIndia AEFI guidelines final draft document
India AEFI guidelines final draft document
Prabir Chatterjee
 
01 introduction to aefi
01 introduction to aefi01 introduction to aefi
01 introduction to aefi
Prabir Chatterjee
 
Aefi investigating & causality assessment
Aefi investigating & causality assessmentAefi investigating & causality assessment
Aefi investigating & causality assessment
Prabir Chatterjee
 
Adverse events following immunization
Adverse events following immunizationAdverse events following immunization
Adverse events following immunization
Optim Associates LLP
 
Covid 19
Covid 19Covid 19
Adverse events fallowing immunization
Adverse events fallowing immunizationAdverse events fallowing immunization
Adverse events fallowing immunization
devika Pj
 
Vaccine safety
Vaccine safetyVaccine safety
Vaccine safety
Sreenivasa Reddy Thalla
 
Vaccine-Pharmacovigilance
Vaccine-PharmacovigilanceVaccine-Pharmacovigilance
Vaccine-Pharmacovigilance
RajatPawar24
 
Evaluation of vaccine safety surveillance.pptx
Evaluation of vaccine safety surveillance.pptxEvaluation of vaccine safety surveillance.pptx
Evaluation of vaccine safety surveillance.pptx
Anurag Gupta
 
VACCINE SAFETY SURVEILLANCE.pptx
VACCINE SAFETY SURVEILLANCE.pptxVACCINE SAFETY SURVEILLANCE.pptx
VACCINE SAFETY SURVEILLANCE.pptx
Arunraina15
 
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology)  V PharmDStudies of vaccine safety (Pharmacoepidemiology)  V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Dr.Sohel Memon
 
05 (b)module g doing causality assessment 2_nov05
05 (b)module g doing causality assessment 2_nov0505 (b)module g doing causality assessment 2_nov05
05 (b)module g doing causality assessment 2_nov05
Prabir Chatterjee
 
Vaccini
VacciniVaccini
Immunization and AEFI
Immunization and AEFIImmunization and AEFI
Immunization and AEFI
Kayode Afolabi
 
Presentation 2 (2).pptx
Presentation 2 (2).pptxPresentation 2 (2).pptx
Presentation 2 (2).pptx
Brahmdutt8
 
Adverse reaction followed by immunization in Paediatrics
Adverse reaction followed by immunization in PaediatricsAdverse reaction followed by immunization in Paediatrics
Adverse reaction followed by immunization in Paediatrics
Nabyendu Biswas
 
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
PVI, PeerView Institute for Medical Education
 

Similar to AEFI.pdf (20)

AEFI.ppt
AEFI.pptAEFI.ppt
AEFI.ppt
 
immunization dnm4 lesson 4.pptx
immunization              dnm4 lesson 4.pptximmunization              dnm4 lesson 4.pptx
immunization dnm4 lesson 4.pptx
 
AEFI monitoring for COVID-19 vaccination
AEFI monitoring for COVID-19 vaccinationAEFI monitoring for COVID-19 vaccination
AEFI monitoring for COVID-19 vaccination
 
India AEFI guidelines final draft document
India AEFI guidelines final draft documentIndia AEFI guidelines final draft document
India AEFI guidelines final draft document
 
01 introduction to aefi
01 introduction to aefi01 introduction to aefi
01 introduction to aefi
 
Aefi investigating & causality assessment
Aefi investigating & causality assessmentAefi investigating & causality assessment
Aefi investigating & causality assessment
 
Adverse events following immunization
Adverse events following immunizationAdverse events following immunization
Adverse events following immunization
 
Covid 19
Covid 19Covid 19
Covid 19
 
Adverse events fallowing immunization
Adverse events fallowing immunizationAdverse events fallowing immunization
Adverse events fallowing immunization
 
Vaccine safety
Vaccine safetyVaccine safety
Vaccine safety
 
Vaccine-Pharmacovigilance
Vaccine-PharmacovigilanceVaccine-Pharmacovigilance
Vaccine-Pharmacovigilance
 
Evaluation of vaccine safety surveillance.pptx
Evaluation of vaccine safety surveillance.pptxEvaluation of vaccine safety surveillance.pptx
Evaluation of vaccine safety surveillance.pptx
 
VACCINE SAFETY SURVEILLANCE.pptx
VACCINE SAFETY SURVEILLANCE.pptxVACCINE SAFETY SURVEILLANCE.pptx
VACCINE SAFETY SURVEILLANCE.pptx
 
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology)  V PharmDStudies of vaccine safety (Pharmacoepidemiology)  V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
 
05 (b)module g doing causality assessment 2_nov05
05 (b)module g doing causality assessment 2_nov0505 (b)module g doing causality assessment 2_nov05
05 (b)module g doing causality assessment 2_nov05
 
Vaccini
VacciniVaccini
Vaccini
 
Immunization and AEFI
Immunization and AEFIImmunization and AEFI
Immunization and AEFI
 
Presentation 2 (2).pptx
Presentation 2 (2).pptxPresentation 2 (2).pptx
Presentation 2 (2).pptx
 
Adverse reaction followed by immunization in Paediatrics
Adverse reaction followed by immunization in PaediatricsAdverse reaction followed by immunization in Paediatrics
Adverse reaction followed by immunization in Paediatrics
 
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
 

More from Chisupa

TOPIC 2. immunizations polies, norms and standards
TOPIC 2. immunizations polies, norms and standardsTOPIC 2. immunizations polies, norms and standards
TOPIC 2. immunizations polies, norms and standards
Chisupa
 
TOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdf
TOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdfTOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdf
TOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdf
Chisupa
 
RED STRATERGY.pdf
RED STRATERGY.pdfRED STRATERGY.pdf
RED STRATERGY.pdf
Chisupa
 
UNIT 4 EXPANDED PROGRAMME OF IMMUNUZATION.pdf
UNIT 4 EXPANDED PROGRAMME OF IMMUNUZATION.pdfUNIT 4 EXPANDED PROGRAMME OF IMMUNUZATION.pdf
UNIT 4 EXPANDED PROGRAMME OF IMMUNUZATION.pdf
Chisupa
 
EXPANDED PROGRAMME OF IMMUNUZATION.pptx
EXPANDED PROGRAMME OF IMMUNUZATION.pptxEXPANDED PROGRAMME OF IMMUNUZATION.pptx
EXPANDED PROGRAMME OF IMMUNUZATION.pptx
Chisupa
 
National mr sia national orientation agenda
National mr sia national orientation agendaNational mr sia national orientation agenda
National mr sia national orientation agenda
Chisupa
 
Too young to die
Too young to dieToo young to die
Too young to die
Chisupa
 
History of pediatric nursing development in zambia
History of pediatric nursing development in zambiaHistory of pediatric nursing development in zambia
History of pediatric nursing development in zambia
Chisupa
 
Parenting styles
Parenting stylesParenting styles
Parenting styles
Chisupa
 
Parenting styles
Parenting stylesParenting styles
Parenting styles
Chisupa
 
Nurses white uniform
Nurses  white uniformNurses  white uniform
Nurses white uniform
Chisupa
 
Family study reflections
Family study reflectionsFamily study reflections
Family study reflections
Chisupa
 
Imci answer key
Imci answer keyImci answer key
Imci answer key
Chisupa
 
Guidelines%20 For%20 Writing%20 Cv[1]
Guidelines%20 For%20 Writing%20 Cv[1]Guidelines%20 For%20 Writing%20 Cv[1]
Guidelines%20 For%20 Writing%20 Cv[1]
Chisupa
 

More from Chisupa (14)

TOPIC 2. immunizations polies, norms and standards
TOPIC 2. immunizations polies, norms and standardsTOPIC 2. immunizations polies, norms and standards
TOPIC 2. immunizations polies, norms and standards
 
TOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdf
TOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdfTOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdf
TOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdf
 
RED STRATERGY.pdf
RED STRATERGY.pdfRED STRATERGY.pdf
RED STRATERGY.pdf
 
UNIT 4 EXPANDED PROGRAMME OF IMMUNUZATION.pdf
UNIT 4 EXPANDED PROGRAMME OF IMMUNUZATION.pdfUNIT 4 EXPANDED PROGRAMME OF IMMUNUZATION.pdf
UNIT 4 EXPANDED PROGRAMME OF IMMUNUZATION.pdf
 
EXPANDED PROGRAMME OF IMMUNUZATION.pptx
EXPANDED PROGRAMME OF IMMUNUZATION.pptxEXPANDED PROGRAMME OF IMMUNUZATION.pptx
EXPANDED PROGRAMME OF IMMUNUZATION.pptx
 
National mr sia national orientation agenda
National mr sia national orientation agendaNational mr sia national orientation agenda
National mr sia national orientation agenda
 
Too young to die
Too young to dieToo young to die
Too young to die
 
History of pediatric nursing development in zambia
History of pediatric nursing development in zambiaHistory of pediatric nursing development in zambia
History of pediatric nursing development in zambia
 
Parenting styles
Parenting stylesParenting styles
Parenting styles
 
Parenting styles
Parenting stylesParenting styles
Parenting styles
 
Nurses white uniform
Nurses  white uniformNurses  white uniform
Nurses white uniform
 
Family study reflections
Family study reflectionsFamily study reflections
Family study reflections
 
Imci answer key
Imci answer keyImci answer key
Imci answer key
 
Guidelines%20 For%20 Writing%20 Cv[1]
Guidelines%20 For%20 Writing%20 Cv[1]Guidelines%20 For%20 Writing%20 Cv[1]
Guidelines%20 For%20 Writing%20 Cv[1]
 

Recently uploaded

Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
70KRISHPATEL
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Swastik Ayurveda
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
AksshayaRajanbabu
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Dr. Jyothirmai Paindla
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
arahmanzai5
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
SwisschemDerma
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
rightmanforbloodline
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 

Recently uploaded (20)

Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 

AEFI.pdf

  • 1. Learning objectives  At the end of the module, the participants will be able to: – Identify adverse events following immunization (AEFIs) – Explain how to report AEFIs
  • 2. What is an AEFI? 1 Which AEFIs are reported? 3 Key issues How likely are AEFIs after vaccinations 2
  • 3. Adverse Event Following Immunization (AEFI)  What is an AEFI? – Any untoward medical occurrence – Takes place after an immunization – Causes concern – it may not necessarily have a causal relationship with the usage of the vaccine  How are AEFIs categorized? Type Severity - Vaccine reaction - Programme error - Coincidental - Injection reaction - Unknown - Minor - Severe • Serious • Non-serious
  • 4. Programme errors  Errors in vaccine preparation, handling, storage, or administration  Preventable  Often constitute the greatest proportion of AEFIs  Identification and correction are of great importance  Examples: – Non-sterile injection – Injection at incorrect site – Administration of frozen vaccine
  • 5. Coincidental events  Occur after vaccination, but not caused by the vaccine or its administration  Occur during infancy when illnesses are common and congenital or early neurological conditions become apparent  Onset temporally associated with vaccination, and inevitable when vaccinating these age groups  Applying normal incidence of disease and death in these age groups along with coverage allows estimation of expected numbers of coincidental events after immunization
  • 6. Injection reactions  Immunization anxiety-related reactions in anticipation to and as a result of an injection of any kind  Not related to the vaccine but to fear of the injection  You may encounter 4 types of injection reactions : – Fainting – Hyperventilation – Vomiting – Convulsions
  • 7. Vaccine reactions can be classified into two levels of severity  Minor reactions – Usually occur within few hours – Resolve quickly – Pose little danger – Local: pain, swelling, redness at injection site – Systemic: fever, malaise, muscle pain, headache, or loss of appetite  Severe reactions- require timely and appropriate management – Usually do not result in long- term problems – Can be disabling – Are rarely life threatening – Include seizures and allergic reactions caused by body’s reaction to a particular component in a vaccine
  • 8. Some severe events can be SERIOUS A serious AEFI- Any untoward medical occurrence that at any dose: – Results in death – Is life threatening – Requires in-patient hospitalization or prolongation of existing hospitalization – Results in persistent or significant disability or incapacity
  • 9. The difference between serious and severe adverse events  A severe reaction is a broader term which includes SERIOUS reactions + reactions that do not necessarily lead to long term problems.  Severe reactions must be reported
  • 10.
  • 11. Objectives of AEFI surveillance Rapidly detect and respond to AEFI Identify, correct and prevent immunization error related reactions Facilitate AEFI causality assessment Recognize AEFI clustering including mild and/or “expected” AEFI Identify potential safety signals and generate hypotheses Generate information for vaccine safety communication
  • 12. Which AEFIs should be reported?  Any severe events or AEFI that is of concern to the parents or health care worker
  • 13. Serious AEFI Potential immunization error Cluster Parental concern Communit y concern Unexpected relationship with vaccination Unexpecte d frequency AEFI Case selection for Reporting* Reporter should NOT assess causality * Events to be reported according to context - Routine surveillance, new vaccine, mass campaign etc
  • 14.  Report the event through existing AEFI reporting systems established by national immunization programs National authorities Community, district, and regional levels Signs or symptoms believed to be related to the vaccine Where to report AEFI's
  • 15. Conducting an AEFI investigation  Some AEFI reports will need further investigation by the immunization programme managers  Components of AEFI investigation: – Identify specifications of implicated vaccine – Examine operational aspects of the programme which may have led to immunization errors – Search for other potential AEFI cases/clustering – Compare background risk to reported rate of AEFI – Confirm (or propose) the diagnosis and determine outcome – In collaboration with experts, determine if AEFI was vaccine- related
  • 16. What information should an AEFI report contain?  Client information  Details about the vaccine – Type – Date – Manufacturer – Lot/expiration date – Site/route of immunization, etc.  Description of adverse event(s) and any associated events  Medical and treatment history  Reporter details
  • 17. Communication with caretakers in case of an AEFI  Reassure the caretaker  Admit uncertainty  Convey that the AEFI will be reported and investigated fully  Keep the community informed with follow-up information
  • 18. Key messages  AEFIs can be minor or severe (which include serious events)  AEFIs should be reported through existing AEFI reporting systems/forms  The safety profile of IPV is excellent  Most infants who get IPV do not experience any side effects  In case of an AEFI – Reassure the caretaker – Admit uncertainty – Investigate fully – Keep the community informed
  • 19. End of module Thank you for your attention!